.Pharmacolibrary.Drugs.S_SensoryOrgans.S01X_OtherOphthalmologicals.S01XA25_Lifitegrast.Lifitegrast .Pharmacolibrary.Drugs.S_SensoryOrgans.S01X_OtherOphthalmologicals.S01XA25_Lifitegrast.Lifitegrast| name: | Lifitegrast | |
| ATC code: | S01XA25 | |
| route: | ophthalmic | |
| compartments: | 1 | |
| dosage: | 5.0 | mg |
| volume of distribution: | 12.8 | L |
| clearance: | 418 | L/h |
| other parameters in model implementation | ||
Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of dry eye disease (keratoconjunctivitis sicca) in adults. It is administered as a topical ophthalmic solution and is FDA-approved for this use.
Pharmacokinetic parameters are largely available from clinical summaries and product labels, as systemic exposure is minimal following ophthalmic administration. Population: Generally healthy adult subjects, both sexes, age ~18-80, normal renal and hepatic function, with dry eye disease.